

**Coverage of any drug intervention discussed in the plans prior authorization guideline is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.**

## Opdivo<sup>®</sup> (nivolumab) (Intravenous)

Document Number: IC-0226

Last Review Date: 07/20/2022

Date of Origin: 01/06/2015

Dates Reviewed: 03/2015, 07/2015, 10/2015, 11/2015, 02/2016, 05/2016, 08/2016, 10/2016, 11/2016, 02/2017, 05/2017, 08/2017, 10/2017, 01/2018, 02/2018, 05/2018, 08/2018, 09/2018, 10/2018, 12/2018, 03/2019, 06/2019, 09/2019, 12/2019, 03/2020, 04/2020, 06/2020, 07/2020, 09/2020, 11/2020, 12/2020, 01/2021, 02/2021, 05/2021, 06/2021, 09/2021, 12/2021, 03/2022, 04/2022, 06/2022, 07/2022

Effective Date: 01/01/2023

### I. Length of Authorization <sup>Δ 1,43,49,50,52,54,65,68</sup>

Coverage will be provided for six (6) months and may be renewed (unless otherwise specified).

- Use in the treatment of Classical Hodgkin Lymphoma in combination with brentuximab vedotin can be authorized up to a maximum of twelve (12) weeks of therapy and may NOT be renewed.
- Neoadjuvant treatment of Merkel Cell Carcinoma can be authorized up to a maximum of two (2) doses and may NOT be renewed.
- Neoadjuvant treatment of NSCLC in combination with platinum-doublet chemotherapy may be authorized for a maximum of three (3) cycles and may NOT be renewed.
- Adjuvant treatment of the following indications may be renewed up to a maximum of one (1) year of therapy:
  - Cutaneous Melanoma
  - Esophageal and Esophagogastric/Gastroesophageal Junction Cancer
  - Urothelial Carcinoma
- The following indications may be renewed up to a maximum of two (2) years of therapy:
  - Cervical Cancer
  - Esophageal Cancer (in combination with fluoropyrimidine- and platinum-containing chemotherapy OR ipilimumab)
  - Esophagogastric/Gastroesophageal Junction Cancer (in combination with fluoropyrimidine- and platinum-containing chemotherapy)
  - Gastric Cancer
  - Malignant Pleural Mesothelioma

- Malignant Peritoneal Mesothelioma
- Non-Small Cell Lung Cancer (in combination with ipilimumab with or without platinum-doublet chemotherapy)
- Renal Cell Carcinoma (in combination with cabozantinib)
- Vulvar Cancer

## II. Dosing Limits

### A. Quantity Limit (max daily dose) [NDC Unit]:

- Opdivo 40 mg/4 mL single-dose vial: 2 vials per 14 days
- Opdivo 100 mg/10 mL single-dose vial: 3 vials per 14 days
- Opdivo 120 mg/12 mL single-dose vial: 3 vials per 14 days
- Opdivo 240 mg/24 mL single-dose vial: 4 vials per 14 days

### B. Max Units (per dose and over time) [HCPCS Unit]:

Indication	Billable Units (BU)	Per unit time (days)
Anal Carcinoma, CNS Metastases, Esophageal Cancer, MPM, MPeM, Merkel Cell Carcinoma, MSI-H/dMMR CRC, MSI-H/dMMR Appendiceal Adenocarcinoma, SCLC, Small Bowel Adenocarcinoma, & Ampullary Adenocarcinoma	340 BU	14 days
Cutaneous Melanoma, Esophagogastric/Gastroesophageal Junction Cancer, Gastric Cancer, Gestational Trophoblastic Neoplasia, HCC, cHL, NSCLC, RCC, SCCHN, Urothelial Carcinoma, Vulvar Cancer, & Cervical Cancer	480 BU	28 days
Uveal Melanoma	1140 BU	14 days
Extranodal NK/ T-Cell Lymphoma	40 BU	14 days
Endometrial Carcinoma	Initial: 340 BU	14 days x 8 doses
	Followed by: 480 BU	28 days

## III. Initial Approval Criteria <sup>1</sup>

Coverage is provided for the following conditions:

- Patient is at least 18 years of age (unless otherwise specified); **AND**

### Universal Criteria

- Patient has not received previous therapy with a programmed death (PD-1/PD-L1)-directed therapy (e.g., cemiplimab, avelumab, pembrolizumab, atezolizumab, durvalumab, dostarlimab, etc.), unless otherwise specified <sup>A</sup>; **AND**

### Ampullary Adenocarcinoma ‡ <sup>2</sup>

- Patient's disease is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); **AND**
- Used in combination with ipilimumab; **AND**
  - Used as first-line therapy for unresectable or metastatic intestinal type disease; **OR**
  - Used as subsequent therapy for disease progression

## Anal Carcinoma ‡<sup>2,6,35</sup>

- Patient has metastatic squamous cell disease; **AND**
- Used as a single agent for subsequent therapy

## Urothelial Carcinoma (Bladder Cancer) † ‡<sup>1,2,30,51,62</sup>

- Used as a single agent; **AND**
  - Used for disease that progressed during or following platinum-containing chemotherapy\* **OR** as second-line treatment after chemotherapy other than a platinum; **AND**
    - Patient has one of the following diagnoses:
      - Locally advanced or metastatic urothelial carcinoma; **OR**
      - Muscle invasive bladder cancer with local recurrence or persistent disease in a preserved bladder ‡; **OR**
      - Metastatic or local bladder cancer recurrence post-cystectomy ‡; **OR**
      - Recurrent or metastatic primary carcinoma of the urethra ‡; **AND**
        - Patient does not have recurrence of stage T3-4 disease or palpable inguinal lymph nodes; **OR**
      - Metastatic upper genitourinary (GU) tract tumors ‡; **OR**
      - Metastatic urothelial carcinoma of the prostate ‡; **OR**
    - Used as adjuvant therapy †; **AND**
      - Patient has urothelial carcinoma of the bladder, bulbar urethra, prostate with stromal invasion, ureter, or renal pelvis; **AND**
      - Patient underwent radical surgical resection or partial cystectomy; **AND**
      - Patient is at high risk of disease recurrence\*\*

### \* *Note:* <sup>10,51,60</sup>

- *If patient was progression free for >12 months after platinum therapy, consider re-treatment with platinum-based therapy if the patient is still platinum eligible (see below for cisplatin- or carboplatin-ineligible comorbidities).*
  - *Cisplatin-ineligible comorbidities may include the following: CrCl < 60 mL/min, PS ≥ 2, hearing loss of ≥ 25 decibels (dB) at two contiguous frequencies, grade ≥ 2 peripheral neuropathy, or NYHA class ≥ 3. Carboplatin may be substituted for cisplatin particularly in those patients with a CrCl < 60 mL/min or a PS of 2.*
  - *Carboplatin-ineligible comorbidities may include the following: CrCl < 30 mL/min, PS > 3, grade > 3 peripheral neuropathy, or NYHA class > 3, etc.*

### \*\* *Note:* <sup>1,62</sup>

- *High risk of disease recurrence is defined as:*
  - *ypT2-ypT4a or ypN+ for patients who received neoadjuvant cisplatin; **OR***
  - *pT3-pT4a or pN+ for patients who did not receive neoadjuvant cisplatin and are also ineligible for or refused adjuvant cisplatin therapy*

### Central Nervous System (CNS) Cancer ‡<sup>2,5,34,41,42</sup>

- Used in one of the following treatment settings:
  - Used as initial treatment in patients with small asymptomatic brain metastases
  - Used for relapsed limited brain metastases with either stable systemic disease or reasonable systemic treatment options
  - Patient has recurrent limited brain metastases
  - Used for recurrent extensive brain metastases with stable systemic disease or reasonable systemic treatment options; **AND**
- Used as a single-agent or in combination with ipilimumab for the treatment of brain metastases in patients with BRAF non-specific melanoma; **OR**
- Used as a single-agent for the treatment of brain metastases in patients with PD-L1 positive non-small cell lung cancer (NSCLC)

### Cervical Cancer ‡<sup>2,49,63</sup>

- Used as subsequent therapy as a single agent; **AND**
- Patient has persistent, recurrent, or metastatic disease; **AND**
- Tumor expresses PD-L1 (e.g., CPS  $\geq$ 1) as determined by an FDA-approved or CLIA-compliant test❖

### Colorectal Cancer (CRC) † ‡<sup>1,2,31,32</sup>

- Patient is at least 12 years of age; **AND**
- Patient's disease must be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); **AND**
- Used as a single agent or in combination with ipilimumab\*; **AND**
  - Used as subsequent therapy for advanced or metastatic disease that progressed following treatment with one of the following:
    - Fluoropyrimidine-, oxaliplatin-, and/or irinotecan-based chemotherapy † ‡; **OR**
    - Non-intensive therapy\*\* ‡; **OR**
  - Used as primary treatment; **AND**
    - Used as neoadjuvant therapy for clinical T4b colon cancer; **OR**
    - Used as neoadjuvant therapy of resectable liver and/or lung metastases; **OR**
    - Used if resection is contraindicated following neoadjuvant therapy for advanced, locally unresectable, or medically inoperable rectal cancer; **OR**
    - Used for unresectable (or medically inoperable) or metastatic disease

\* Single agent nivolumab should be used in patients who are not candidates for intensive therapy.

\*\* Except if received previous fluoropyrimidine, with improvement in functional status.

### Appendiceal Adenocarcinoma – Colon Cancer ‡<sup>2</sup>

- Patient's disease must be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); **AND**

- Used as a single agent or in combination with ipilimumab\*; **AND**
  - Used as subsequent therapy for advanced or metastatic disease that progressed following previous oxaliplatin- irinotecan- and/or fluoropyrimidine-based therapy; **OR**
  - Used as initial therapy for advanced or metastatic disease

\* Single agent nivolumab should be used in patients who are not candidates for intensive therapy.

### **Esophageal Cancer and Esophagogastric/Gastroesophageal Junction Cancers † ‡ Φ 1,2,44,52,56,69**

- Used as first-line therapy; **AND**
  - Patient has esophageal squamous cell carcinoma (ESCC) †; **AND**
    - Patient has unresectable advanced or metastatic disease; **AND**
      - Used in combination with fluoropyrimidine- and platinum-containing chemotherapy; **OR**
      - Used in combination with ipilimumab; **OR**
  - Patient has adenocarcinoma; **AND**
    - Patient is not a surgical candidate or has unresectable advanced, recurrent, or metastatic disease; **AND**
    - Used in combination with fluoropyrimidine- and platinum-containing chemotherapy; **OR**
- Used as subsequent therapy; **AND**
  - Patient has esophageal squamous cell carcinoma (ESCC) †; **AND**
  - Patient is not a surgical candidate or has unresectable advanced, recurrent, or metastatic disease; **AND**
  - Used as a single agent; **OR**
- Used as adjuvant treatment of completely resected disease †; **AND**
  - Used as a single agent in patients with residual disease following neoadjuvant chemoradiotherapy (CRT)

### **Gastric Cancer † ‡ Φ 1,2,53,56**

- Patient is not a surgical candidate or has unresectable, advanced, recurrent, or metastatic disease; **AND**
  - Used as first-line therapy in combination with fluoropyrimidine- and platinum-containing chemotherapy

### **Gestational Trophoblastic Neoplasia † 2,36**

- Used as single-agent therapy for multiagent chemotherapy-resistant disease; **AND**
  - Patient has intermediate placental site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT); **AND**
    - Patient has recurrent or progressive disease; **AND**
    - Patient was previously treated with a platinum-based regimen; **OR**
  - Patient has high risk disease (i.e., ≥7 Prognostic score or stage IV disease)

## Squamous Cell Carcinoma of the Head and Neck (SCCHN) † ‡ 1,2,29

- Patient has Cancer of the Nasopharynx; **AND**
  - Used in combination with cisplatin and gemcitabine for oligometastatic or metastatic disease; **OR**
- Patient has Very Advanced Head and Neck Cancer\*; **AND**
  - Patient has nasopharyngeal cancer; **AND**
    - Used in combination with cisplatin and gemcitabine for patients with performance status 0-1; **AND**
    - Used for one of the following:
      - Unresectable locoregional recurrence with prior radiation therapy (RT)
      - Unresectable second primary with prior RT
      - Unresectable persistent disease with prior RT
      - Recurrent/persistent disease with distant metastases; **OR**
  - Patient has NON-nasopharyngeal cancer; **AND**
    - Used as a single agent; **AND**
    - Patient has unresectable, recurrent, persistent, or metastatic disease; **AND**
    - Disease has progressed on or after platinum-containing chemotherapy

*\* Very Advanced Head and Neck Cancer includes: newly diagnosed locally advanced T4b (M0) disease, newly diagnosed unresectable nodal disease, metastatic disease at initial presentation (M1), or recurrent or persistent disease.*

## Hepatocellular Carcinoma (HCC) † ‡ Φ 1,2,21

- Used in combination with ipilimumab; **AND**
- Used as subsequent therapy for progressive disease; **AND**
- Patient has Child-Pugh Class A hepatic impairment; **AND**
  - Patient was previously treated with sorafenib †; **OR**
  - Patient has unresectable disease and is not a transplant candidate; **OR**
  - Patient has liver-confined disease that is inoperable by performance status, comorbidity, or with minimal or uncertain extrahepatic-disease; **OR**
  - Patient has metastatic disease or extensive liver tumor burden

## Adult Classical Hodgkin Lymphoma (cHL) † ‡ Φ 1,2,27,28

- Used as a single agent; **AND**
  - Patient has relapsed or progressive disease after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; **OR**
  - Used as third-line or subsequent therapy OR as palliative therapy in patients > 60 years of age; **AND**
    - Patient has relapsed or progressive disease after autologous HSCT; **OR**

- Patient has relapsed or refractory disease and is transplant-ineligible based on comorbidities or failure of second-line chemotherapy; **OR**
- Patient is post-allogeneic stem-cell transplant; **OR**
- Used in combination with brentuximab vedotin; **AND**
  - Used as subsequent therapy (if not previously used) for relapsed or refractory disease

**Pediatric Classical Hodgkin Lymphoma (cHL) † ‡<sup>2,27,28</sup>**

- Patient age is 18 years and under\*; **AND**
- Patient has relapsed or refractory disease; **AND**
- Used in patients heavily pretreated with platinum or anthracycline-based chemotherapy or if a decrease in cardiac function was observed; **AND**
  - Used as subsequent therapy (if not previously used); **AND**
    - Used as a single agent or in combination with brentuximab vedotin; **OR**
  - Used as re-induction therapy; **AND**
    - Used in combination with brentuximab vedotin; **OR**
    - Used in combination with brentuximab vedotin and radiation therapy (ISRT) in highly favorable patients who may avoid autologous stem cell rescue (ASCR) (*i.e., initial stage other than IIIB or IVB, no prior exposure to RT, duration of CR1 >1 year, absence of extranodal disease or B symptoms at relapse*)

\* Pediatric Hodgkin Lymphoma may be applicable to adolescent and young adult (AYA) patients up to the age of 39 years.

**Renal Cell Carcinoma (RCC) † ‡<sup>1,2,25,26</sup>**

- Used in combination with ipilimumab for clear cell histology; **AND**
  - Used as first-line therapy in patients with advanced, relapsed, or stage IV disease with poor or intermediate risk; **OR**
  - Used as first-line therapy in patients with relapsed or stage IV disease with favorable risk; **OR**
  - Used as subsequent therapy in patients with relapsed or stage IV disease; **OR**
- Used as a single agent; **AND**
  - Used as subsequent therapy in patients with advanced, relapsed, or stage IV disease and clear cell histology; **OR**
  - Patient has relapsed or stage IV disease and non-clear cell histology; **OR**
- Used in combination with cabozantinib (Cabometyx only) for clear cell histology; **AND**
  - Used as first-line therapy for advanced, relapsed, or stage IV disease; **OR**
  - Used as subsequent therapy in patients with relapsed or stage IV disease

**Malignant Peritoneal Mesothelioma (MPeM) † ‡<sup>2,64</sup>**

- Used as a single agent or in combination with ipilimumab as subsequent therapy (if not administered first-line); **OR**

- Used in combination with ipilimumab as first-line therapy; **AND**
  - Patient has unresectable diffuse disease; **OR**
  - Patient has unresectable recurrent benign multicystic or well-differentiated papillary disease

*\*Note: May also be used for pericardial mesothelioma and tunica vaginalis testis mesothelioma.*

### **Malignant Pleural Mesothelioma (MPM) † ‡ ◻ 1,2,37,38,47,64**

- Used as a single agent or in combination with ipilimumab as subsequent therapy (if not administered first-line); **OR**
- Used in combination with ipilimumab as first-line therapy; **AND**
  - Patient has stage IIIB or IV disease; **OR**
  - Patient has sarcomatoid or biphasic histology; **OR**
  - Disease is medically inoperable or unresectable

*\*Note: May also be used for pericardial mesothelioma and tunica vaginalis testis mesothelioma.*

### **Cutaneous Melanoma † ‡ ◻ 1,2,15-18**

- Used as first-line therapy for unresectable or metastatic\* disease; **AND**
  - Used as a single agent or in combination with ipilimumab; **OR**
- Used as initial therapy for limited resectable disease; **AND**
  - Used as a single agent; **AND**
    - Patient has stage III disease with clinical satellite/in-transit metastases; **OR**
    - Patient has local satellite/in-transit recurrence; **OR**
- Used as subsequent therapy for unresectable or metastatic\* disease; **AND**
  - Used as re-induction therapy in patients who experienced disease control (*i.e., complete or partial response or stable disease*) and no residual toxicity from prior anti-PD-1 immunotherapy, but subsequently have disease progression/relapse > 3 months after treatment discontinuation; **AND**
    - Used as a single agent or in combination with ipilimumab; **OR**
  - Used after disease progression or maximum clinical benefit from BRAF-targeted therapy (e.g., dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib, etc.); **AND**
    - Used as a single agent or in combination with ipilimumab if anti-PD-1 was not previously used; **OR**
    - Used in combination with ipilimumab for patients who progressed on single agent anti-PD-1 therapy; **OR**
- Used as adjuvant treatment as a single agent; **AND**
  - Patient has lymph node involvement and has undergone complete resection, complete lymph node dissection (CLND), therapeutic lymph node dissection (TLND), or nodal basin ultrasound surveillance; **OR**



- Patient has satellite/in-transit metastases or recurrence and has no evidence of disease after complete excision; **OR**
- Patient has undergone TLND and/or complete resection of nodal recurrence; **OR**
- Patient has undergone complete resection of metastatic disease; **OR**
- Patient has oligometastatic disease and no evidence of disease following metastasis-directed therapy (i.e., stereotactic ablative therapy or complete resection) or systemic therapy

*\*Metastatic disease includes stage III unresectable/borderline resectable disease with clinically positive node(s) or clinical satellite/in-transit metastases, as well as unresectable local satellite/in-transit recurrence, unresectable nodal recurrence, and widely disseminated distant metastatic disease.*

### **Uveal Melanoma ‡ 2,19,20**

- Patient has distant metastatic disease; **AND**
- Used as a single agent or in combination with ipilimumab

### **Merkel Cell Carcinoma ‡ 2,4,33,65**

- Used as a single agent; **AND**
  - Used as neoadjuvant treatment for regional, pathologic N+ disease; **OR**
  - Used for primary or recurrent metastatic disseminated disease

### **Non-Small Cell Lung Cancer (NSCLC) † 1,2,22,23,45,46**

- Used for resectable (tumors  $\geq$  4 cm or node positive) disease; **AND**
  - Used as neoadjuvant therapy in combination with platinum-doublet chemotherapy (e.g., paclitaxel and carboplatin, pemetrexed and cisplatin, or gemcitabine and cisplatin); **OR**
- Used for recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**
  - Used as first-line therapy; **AND**
    - Used for one of the following:
      - Patients with a performance status (PS) 0-1 who have tumors that are negative for actionable molecular biomarkers\*\* and PD-L1 expression <1%
      - Patients with a PS 0-1 who are positive for one of the following molecular biomarkers: EGFR exon 20, KRAS G12C, BRAF V600E, NTRK1/2/3 gene fusion, MET exon 14 skipping, or RET rearrangement
      - PD-L1 expression-positive (PD-L1  $\geq$ 1%) tumors, as detected by an FDA or CLIA compliant test❖, that are negative for actionable molecular biomarkers\*\*;
  - Used in combination with ipilimumab; **OR**

- Used in combination with ipilimumab and platinum-doublet chemotherapy (e.g., pemetrexed and either carboplatin or cisplatin for nonsquamous cell histology, paclitaxel and carboplatin for squamous cell histology, etc.); **OR**
- Used as subsequent therapy; **AND**
  - Used as a single agent; **OR**
  - Used for one of the following:
    - Patients with a PS 0-1 who received prior targeted therapy§ for one of the following molecular biomarkers: EGFR S768I, L861Q, and/or G719X, or ROS1 rearrangement
    - Patients with a PS 0-1 who are positive for one of the following molecular biomarkers: BRAF V600E, NTRK1/2/3 gene fusion, MET exon 14 skipping, or RET rearrangement; **AND**
  - Used in combination with ipilimumab; **OR**
  - Used in combination with ipilimumab, pemetrexed, and either carboplatin or cisplatin for nonsquamous cell histology; **OR**
  - Used in combination with ipilimumab, paclitaxel, and carboplatin for squamous cell histology; **OR**
- Used as continuation maintenance therapy in combination with ipilimumab; **AND**
  - Patient has achieved a response or stable disease following first-line therapy with nivolumab and ipilimumab with or without chemotherapy

*\*\* Note: Actionable molecular genomic biomarkers include EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping mutation, and RET rearrangement. If there is insufficient tissue to allow testing for all of EGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, and RET, repeat biopsy and/or plasma testing should be done. If these are not feasible, treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.*

### **Small Bowel Adenocarcinoma ‡<sup>2,31,39</sup>**

- Patient has advanced or metastatic disease that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); **AND**
- Used as a single agent or in combination with ipilimumab; **AND**
  - Used as initial therapy; **OR**
  - Used as subsequent therapy for patients with no prior oxaliplatin exposure in the adjuvant treatment setting and no contraindication to oxaliplatin therapy

### **Small Cell Lung Cancer (SCLC) ‡<sup>2,24,61</sup>**

- Used as subsequent systemic therapy as a single agent; **AND**
  - Disease has relapsed following a complete or partial response or stable disease with primary treatment (*excluding use in patients who progressed on maintenance atezolizumab or durvalumab at time of relapse*); **OR**
  - Used for primary progressive disease

### **Extranodal NK/T-Cell Lymphomas ‡<sup>2,40</sup>**

- Used as a single agent for relapsed or refractory disease; **AND**
- Used following additional therapy with an alternative asparaginase-based chemotherapy regimen not previously used; **AND**
- Participation in a clinical trial is unavailable

**Endometrial Carcinoma (Uterine Neoplasms) ‡ 2,48**

- Used as a single agent; **AND**
- Used as second-line therapy for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) recurrent or metastatic disease

**Vulvar Cancer (Squamous Cell Carcinoma) ‡ 2,49**

- Used as a single agent; **AND**
- Used as second-line therapy for HPV-related advanced, recurrent, or metastatic disease

❖ *If confirmed using an immunotherapy assay-<http://www.fda.gov/CompanionDiagnostics>*

† FDA Approved Indication(s); ‡ Compendia recommended indication(s); Ⓢ Orphan Drug

Genomic Aberration/Mutational Driver Targeted Therapies (Note: not all inclusive, refer to guidelines for appropriate use) §				
Sensitizing EGFR mutation-positive tumors	ALK rearrangement-positive tumors	ROS1 rearrangement-positive tumors	BRAF V600E-mutation positive tumors	NTRK1/2/3 gene fusion positive tumors
<ul style="list-style-type: none"> <li>– Afatinib</li> <li>– Erlotinib</li> <li>– Dacomitinib</li> <li>– Gefitinib</li> <li>– Osimertinib</li> <li>– Amivantamab (exon-20 insertion)</li> <li>– Mobocertinib (exon-20 insertion)</li> </ul>	<ul style="list-style-type: none"> <li>– Alectinib</li> <li>– Brigatinib</li> <li>– Ceritinib</li> <li>– Crizotinib</li> <li>– Lorlatinib</li> </ul>	<ul style="list-style-type: none"> <li>– Ceritinib</li> <li>– Crizotinib</li> <li>– Entrectinib</li> <li>– Lorlatinib</li> </ul>	<ul style="list-style-type: none"> <li>– Dabrafenib ± trametinib</li> <li>– Vemurafenib</li> </ul>	<ul style="list-style-type: none"> <li>– Larotrectinib</li> <li>– Entrectinib</li> </ul>
PD-L1 tumor expression ≥1%	PD-L1 tumor expression ≥50%	MET exon-14 skipping mutations	RET rearrangement-positive tumors	KRAS G12C mutation positive tumors
<ul style="list-style-type: none"> <li>– Pembrolizumab</li> <li>– Atezolizumab</li> <li>– Nivolumab + ipilimumab</li> </ul>	<ul style="list-style-type: none"> <li>– Pembrolizumab</li> <li>– Atezolizumab</li> <li>– Nivolumab + ipilimumab</li> <li>– Cemiplimab</li> </ul>	<ul style="list-style-type: none"> <li>– Capmatinib</li> <li>– Crizotinib</li> <li>– Tepotinib</li> </ul>	<ul style="list-style-type: none"> <li>– Selpercatinib</li> <li>– Cabozantinib</li> <li>– Pralsetinib</li> </ul>	<ul style="list-style-type: none"> <li>– Sotorasib</li> </ul>

**IV. Renewal Criteria** Δ 1,2,4-6,15-42,43,49,50,52,54,68

Coverage may be renewed based upon the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe infusion-related reactions, complications of allogeneic hematopoietic stem cell transplantation (HSCT), severe immune-mediated adverse reactions (i.e., pneumonitis, colitis, hepatitis, endocrinopathies, nephritis/renal dysfunction, adverse skin reactions/rash, etc.), hepatotoxicity when taken with cabozantinib, etc.; **AND**

- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- For the following indications, patient has not exceeded a maximum of two (2) years of therapy:
  - Cervical Cancer
  - Esophageal Cancer (in combination with fluoropyrimidine- and platinum-containing chemotherapy OR ipilimumab)
  - Esophagogastric/Gastroesophageal Junction Cancer (in combination with fluoropyrimidine- and platinum-containing chemotherapy)
  - Gastric Cancer
  - Malignant Pleural Mesothelioma
  - Malignant Peritoneal Mesothelioma
  - Non-Small Cell Lung Cancer (in combination with ipilimumab with or without platinum-doublet chemotherapy)
  - Renal Cell Carcinoma (in combination with cabozantinib)
  - Vulvar Cancer

#### **Cutaneous Melanoma (adjuvant therapy)**

- Patient has not exceeded a maximum of one (1) year of therapy

#### **Cutaneous Melanoma (re-induction therapy)**

- *Refer to Section III for criteria (see Cutaneous Melanoma – Used for retreatment of disease as re-induction)*

#### **Non-Small Cell Lung Cancer (neoadjuvant therapy in combination with platinum-doublet chemotherapy)**

- Patient has not exceeded a maximum of three (3) cycles

#### **Non-Small Cell Lung Cancer (maintenance therapy)**

- *Refer to Section III for criteria*

#### **Urothelial Carcinoma (adjuvant therapy)**

- Patient has not exceeded a maximum of one (1) year of therapy

#### **Esophageal and Esophagogastric/Gastroesophageal Junction Cancer (adjuvant therapy)**

- Patient has not exceeded a maximum of one (1) year of therapy

#### **Classical Hodgkin Lymphoma (in combination with brentuximab vedotin)**

- Patient has not exceeded a maximum of twelve (12) weeks of therapy

#### **Merkel Cell Carcinoma (neoadjuvant therapy)**

- Patient has not exceeded a maximum of two (2) doses

#### **Δ Notes:**

- Patients responding to therapy who relapse  $\geq 6$  months after discontinuation due to duration (i.e., receipt of 24 months of therapy) are eligible to re-initiate PD-directed therapy.

- Patients who complete adjuvant therapy and progress  $\geq$  6 months after discontinuation are eligible to re-initiate PD-directed therapy for metastatic disease.
- Patients whose tumors, upon re-biopsy, demonstrate a change in actionable mutation (e.g., MSS initial biopsy; MSI-H subsequent biopsy) may be eligible to re-initiate PD-directed therapy and will be evaluated on a case-by-case basis.

## V. Dosage/Administration <sup>Δ</sup> 1,4-6,24,31-42,48-50,54,58,59,61,65,68

Indication	Dose
Ampullary Adenocarcinoma & Anal Cancer	Administer 240 mg intravenously every 2 weeks, 480 mg intravenously every 4 weeks, or 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity
Urothelial Carcinoma (Bladder Cancer)	<p><u>Second-line or subsequent treatment:</u></p> <ul style="list-style-type: none"> <li>• Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>Adjuvant treatment:</u></p> <ul style="list-style-type: none"> <li>• Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease recurrence or unacceptable toxicity for up to 1 year</li> </ul>
CNS Metastases from Melanoma	<p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>• Administer 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>• Administer 1 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity</li> </ul>
CNS Metastases from NSCLC	Administer 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity
Esophageal Squamous Cell Carcinoma (ESCC)	<p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>• Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with fluoropyrimidine- and platinum-containing chemotherapy:</u></p> <ul style="list-style-type: none"> <li>• Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity for up to 2 years</li> </ul> <p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>• Administer 3 mg/kg every 2 weeks or 360 mg intravenously every 3 weeks, with ipilimumab every 6 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul>
Esophageal and Esophagogastric/Gastroesophageal	Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks for up to 1 year

Junction Cancer (Adjuvant Therapy)	
Esophageal and Esophagogastric/Gastroesophageal Junction Cancer (Adenocarcinoma)	<p><u>In combination with fluoropyrimidine- and platinum-containing chemotherapy:</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 360 mg intravenously every 3 weeks until disease progression or unacceptable toxicity for up to 2 years</li> </ul>
Gastric Cancer	Administer 240 mg intravenously every 2 weeks or 360 mg intravenously every 3 weeks until disease progression or unacceptable toxicity for up to 2 years
MSI-H/dMMR CRC	<p><u>Adult patients and for pediatric patients ≥ 12 years and &gt; 40 kg:</u></p> <ul style="list-style-type: none"> <li><b>As a single agent:</b> Administer 3 mg/kg intravenously every 2 weeks, or 240 mg intravenously every 2 weeks, or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> <li><b>In combination with ipilimumab:</b> <ul style="list-style-type: none"> <li><u>Primary/initial treatment</u> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously every 2 weeks, with ipilimumab every 6 weeks, until disease progression or unacceptable toxicity</li> </ul> </li> <li><u>Subsequent therapy/disease progression</u> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then follow with the single agent regimen</li> </ul> </li> </ul> </li> </ul> <p><u>Pediatric patients ≥ 12 years and &lt; 40 kg:</u></p> <ul style="list-style-type: none"> <li><b>As a single agent:</b> Administer 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity</li> <li><b>In combination with ipilimumab:</b> <ul style="list-style-type: none"> <li><u>Primary/initial treatment</u> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously every 2 weeks, with ipilimumab every 6 weeks, until disease progression or unacceptable toxicity</li> </ul> </li> <li><u>Subsequent therapy/disease progression</u> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then follow with the single agent regimen</li> </ul> </li> </ul> </li> </ul>
MSI-H/dMMR Appendiceal Adenocarcinoma	<ul style="list-style-type: none"> <li><b>As a single agent:</b> Administer 3 mg/kg intravenously every 2 weeks, or 240 mg intravenously every 2 weeks, or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> <li><b>In combination with ipilimumab:</b> <ul style="list-style-type: none"> <li><u>Primary/initial treatment</u> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously every 2 weeks, with ipilimumab every 6 weeks, until disease progression or unacceptable toxicity</li> </ul> </li> <li><u>Subsequent therapy/disease progression</u> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then follow with the single agent regimen</li> </ul> </li> </ul> </li> </ul>
SCCHN & Gestational Trophoblastic Neoplasia (GTN)	Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity

Hepatocellular Carcinoma (HCC)	<p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>Administer 1 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul>
cHL	<p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with brentuximab vedotin</u></p> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously every 3 weeks for up to 12 weeks (4 cycles)</li> </ul>
Renal Cell Carcinoma (RCC)	<p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then follow with single agent regimen</li> </ul> <p><u>In combination with cabozantinib (Cabometyx):</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity for up to 2 years</li> </ul>
Malignant Pleural Mesothelioma (MPM) & Malignant Peritoneal Mesothelioma (MPeM)	<p><u>Single agent subsequent therapy:</u></p> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity for up to 2 years</li> </ul> <p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>Subsequent Therapy <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously every 2 weeks, with ipilimumab every 6 weeks, until disease progression or unacceptable toxicity for up to 2 years; <b>OR</b></li> <li>Administer 240 mg intravenously every 2 weeks, with ipilimumab every 6 weeks (ipilimumab given for a total of 4 doses), until disease progression or unacceptable toxicity for up to 2 years</li> </ul> </li> <li>Initial Therapy <ul style="list-style-type: none"> <li>Administer 360 mg intravenously every 3 weeks or 3 mg/kg every 2 weeks, with ipilimumab every 6 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> </li> </ul>
Cutaneous Melanoma	<p><u>Single agent (excluding adjuvant therapy):</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with ipilimumab (excluding adjuvant therapy):</u></p> <ul style="list-style-type: none"> <li>Administer 1 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then follow with single agent regimen</li> </ul> <p><u>Adjuvant treatment:</u></p>

	<ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease recurrence or unacceptable toxicity for up to 1 year</li> </ul>
Uveal Melanoma	<p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>Administer up to 10 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>Administer 1 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity</li> </ul>
Merkel Cell Carcinoma	<p><u>Neoadjuvant treatment:</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks (days 1 and 15) for a total of 2 doses</li> </ul> <p><u>Primary or recurrent metastatic disease:</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity</li> </ul>
NSCLC	<p><u>Neoadjuvant treatment in combination with platinum-doublet chemotherapy:</u></p> <ul style="list-style-type: none"> <li>Administer 360 mg intravenously with platinum-doublet chemotherapy every 3 weeks for 3 cycles.</li> </ul> <p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>Administer 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>Administer 360 mg intravenously every 3 weeks, with ipilimumab every 6 weeks, until disease progression or unacceptable toxicity for up to 2 years</li> </ul> <p><u>In combination with ipilimumab and platinum-doublet chemotherapy:</u></p> <ul style="list-style-type: none"> <li>Administer 360 mg intravenously every 3 weeks, with ipilimumab every 6 weeks and histology-based platinum-doublet chemotherapy every 3 weeks for 2 cycles, then continue 360 mg every 3 weeks until disease progression or unacceptable toxicity for up to 2 years</li> </ul>
Small Bowel Adenocarcinoma	<p><u>Single agent:</u></p> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously every 2 weeks, or 240 mg intravenously every 2 weeks, or 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity</li> </ul> <p><u>In combination with ipilimumab:</u></p> <ul style="list-style-type: none"> <li>Administer 3 mg/kg intravenously, with ipilimumab on the same day, every 3 weeks for 4 doses, then 3 mg/kg or 240 mg intravenously every 2 weeks until disease progression or unacceptable toxicity</li> </ul>
SCLC	Administer 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity
Extranodal NK/T-Cell Lymphoma	Administer 40 mg intravenously every 2 weeks until disease progression or unacceptable toxicity
Endometrial Carcinoma	Administer 3 mg/kg intravenously every 2 weeks for 8 doses, then 480 mg intravenously every 4 weeks until disease progression or unacceptable toxicity



Vulvar Cancer & Cervical Cancer	Administer 240 mg intravenously every 2 weeks until disease progression or unacceptable toxicity for up to 2 years
<p><u>Dosing should be calculated using actual body weight and not flat dosing (as applicable) based on the following:</u></p> <p><u>Weight ≥ 74 kg:</u></p> <ul style="list-style-type: none"> <li>Standard dose 480 mg IV every 4 weeks</li> </ul> <p><u>Weight is 67 kg to 73 kg:</u></p> <ul style="list-style-type: none"> <li>Use 440 mg IV every 4 weeks</li> </ul> <p><u>Weight is ≤ 66kg:</u></p> <ul style="list-style-type: none"> <li>Use 400 mg IV every 4 weeks</li> </ul> <p><b>-OR-</b></p> <p><u>Weight &gt; 67 kg:</u></p> <ul style="list-style-type: none"> <li>Standard dose 240 mg IV every 2 weeks</li> </ul> <p><u>Weight is 53 kg to 67 kg:</u></p> <ul style="list-style-type: none"> <li>Use 200 mg IV every 2 weeks</li> </ul> <p><u>Weight is &lt; 53kg:</u></p> <ul style="list-style-type: none"> <li>Use 160 mg IV every 2 weeks</li> </ul> <p><i>Note: This information is not meant to replace clinical decision making when initiating or modifying medication therapy and should only be used as a guide. Patient-specific variables should be taken into account.</i></p>	

## VI. Billing Code/Availability Information

### HCPCS Code:

- J9299 – Injection, nivolumab, 1 mg; 1 billable unit = 1 mg

### NDC(s):

- Opdivo 40 mg/4 mL single-dose vial: 00003-3772-xx
- Opdivo 100 mg/10 mL single-dose vial: 00003-3774-xx
- Opdivo 120 mg/12 mL single-dose vial: 00003-3756-xx
- Opdivo 240 mg/24 mL single-dose vial: 00003-3734-xx

## VII. References

- Opdivo [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; May 2022. Accessed June 2022.
- Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) nivolumab. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2022.

3. Scherpereel A, Mazieres J, Greillier L, et al. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. [Abstract]. *J Clin Oncol* 2017;35: Abstract LBA 8507.
4. Walocko FM, Scheier BY, Harms PW, et al. Metastatic Merkel cell carcinoma response to nivolumab. *J Immunother Cancer*. 2016 Nov 15;4:79.
5. Tawbi HA-H, Forsyth PAJ, Algazi AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. *J Clin Oncol* 2017;35(15\_suppl):abstr 9507.
6. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. *Lancet Oncol*. 2017 Apr;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18.
7. Zhao X, Ivaturi V, Gopalakrishnan M, et al. Abstract CT 101: A model-based exposure-response (E-R) assessment of a nivolumab (NIVO) 4-weekly (Q4W) dosing schedule across multiple tumor types. *Cancer Res* July 1 2017 (77) (13 Supplement) CT101; DOI: 10.1158/1538-7445.AM2017-CT101.
8. Zhao X, Suryawanshi M, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240 mg flat dose relative to a 3 mg/kg dosing regimen in patients with advanced tumors. *Ann Oncol* 2017; 28:2002-2008.
9. Feng Y, Xiaoning W, Bajaj G, et al. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. *ClinCa Res* 2017;23(18): 5394-5405.
10. Gupta S, Sonpavde G, Grivas P, et al. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). *J Clin Oncol*. 2019 Mar 1;37(7\_suppl):451.
11. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med* 2018; 378:2093-2104.
12. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract*. 2018 Mar;14(3):e130-e136.
13. Hematology/Oncology Pharmacy Association (2019). Intravenous Cancer Drug Waste Issue Brief. Retrieved from [http://www.hoparx.org/images/hopa/advocacy/Issue-Briefs/Drug\\_Waste\\_2019.pdf](http://www.hoparx.org/images/hopa/advocacy/Issue-Briefs/Drug_Waste_2019.pdf)
14. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. *BMJ*. 2016 Feb 29;352:i788.
15. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

16. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
17. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
18. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med*. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
19. Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer*. 2016 Nov 15;122(21):3344-3353. doi: 10.1002/cncr.30258. Epub 2016 Aug 17.
20. Piulats JM, Cruz-Merino LDL, Garcia MTC, et al. Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962). *J Clin Oncol* 2017; 35 Abstr 9533.
21. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *Lancet*. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
22. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
23. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
24. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.
25. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
26. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
27. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. *J Clin Oncol*. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27.
28. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.

29. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med*. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.
30. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26.
31. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. *Lancet Oncol*. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.
32. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. *J Clin Oncol*. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
33. Topalian SL, Bhatia S, Hollebecque A, et al. Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC). DOI: 10.1158/1538-7445.AM2017-CT074 Published July 2017.
34. Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol*. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.
35. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Anal Carcinoma. Version 1.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2022.
36. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Gestational Trophoblastic Neoplasia. Version 1.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2022.
37. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. *Lancet Oncol*. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16.
38. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a

- prospective, single-arm, phase 2 trial. *Lancet Respir Med*. 2019 Mar;7(3):260-270. doi: 10.1016/S2213-2600(18)30420-X. Epub 2019 Jan 16.
39. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Small Bowel Adenocarcinoma. Version 1.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2022.
40. Chan TSY, Li J, Loong F, et al. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety. *Ann Hematol*. 2018 Jan;97(1):193-196. doi: 10.1007/s00277-017-3127-2. Epub 2017 Sep 6.
41. Goldman JW, Crino L, Vokes EE, et al. Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). *J Clin Oncol* 34, no. 15\_suppl (May 20, 2016) 9038-9038. DOI: 10.1200/JCO.2016.34.15\_suppl.9038.
42. Gauvain C, Vauleon E, Chouaid C, et al. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. *Lung Cancer*. 2018 Feb; 116:62-66. doi: 10.1016/j.lungcan.2017.12.008.
43. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Non-Small Cell Lung Cancer. Version 3.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed May 2022.
44. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(11):1506-1517. doi:10.1016/S1470-2045(19)30626-6.
45. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*. 2019;381(21):2020-2031. doi:10.1056/NEJMoa1910231.
46. Reck M, Ciuleanu T-E, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA [abstract]. *J Clin Oncol* 2020;38:Abstract 9501-9501.
47. Zalcman G, Peters S, Mansfield AS, et al. Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. *Journal of Clinical Oncology* 2017 35:15\_suppl, TPS8581-TPS8581

48. Azad NS, Gray RJ, Overman MJ, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. *J Clin Oncol*. 2020 Jan 20;38(3):214-222.
49. Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. *J Clin Oncol*. 2019 Nov 1;37(31):2825-2834.
50. Choueiri TK, Powles T, Burotto M, et al. 696O\_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Volume 31, SUPPLEMENT 4, S1159, September 01, 2020.
51. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Bladder Cancer. Version 1.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed May 2022.
52. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers. Version 2.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed June 2022.
53. Referenced with permission from the NCCN Clinical Practice Guidelines (NCCN Guidelines®) Gastric Cancer. Version 2.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed June 2022.
54. Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractor Hodgkin lymphoma. *Blood*. 2018 Mar 15;131 (11):1183-1194.
55. Cole PD, Mauz-Körholz C, Mascarin M, et al. HL-032: Nivolumab and Brentuximab Vedotin (BV)-Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study. *Clinical Lymphoma Myeloma and Leukemia*. Volume 20, Supplement 1, September 2020, Pages S245-S246.
56. Moehler M, Shitara K, Garrido M, et al. Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal

- junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. [abstract]. Presented at the Oral Presentation presented at the ESMO 2020 Annual Meeting; September 19-21, 2020; Virtual Meeting.
57. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med*. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
  58. Nivolumab. Micromedex Solutions. Greenwood Village, CO: Truven Health Analytics. <http://micromedex.com/>. Updated July 1, 2021. Accessed July 2021.
  59. Lenz HJ, Lonardi S, Zagonel V, et al. Nivolumab (NIVO) + low-dose ipilimumab (IP) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update [abstract]. *Journal of Clinical Oncology* 2019;37:3521-3521.
  60. Bellmunt, J. (2022). Treatment of metastatic urothelial cancer of the bladder and urinary tract. In Lerner SP, Shah S (Eds.), *UptoDate*. Accessed May 12, 2022. Available from [https://www.uptodate.com/contents/treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract?search=cisplatin%20ineligible&source=search\\_result&selectedTitle=1~150&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract?search=cisplatin%20ineligible&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1).
  61. Ready NE, Ott PA, Hellmann MD, et al. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. *J Thorac Oncol*. 2020 Mar;15(3):426-435. doi: 10.1016/j.jtho.2019.10.004.
  62. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med*. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442.
  63. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Cervical Cancer. Version 1.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2022.
  64. Fennell DA, Ewings S, Ottensmeier C, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. *Lancet Oncol* 2021; 22:1530.
  65. Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. *J Clin Oncol*. 2020;38(22):2476-2487. doi:10.1200/JCO.20.00201.
  66. Forde PM, Spicer J, Lu S, et al (2021). Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (1B-IIIa) non-small cell lung cancer NSCLC in the phase 3 CheckMate 816 trial. American Association for Cancer Research Annual Meeting 2021. Abstract CT003.

67. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Malignant Peritoneal Mesothelioma. Version 1.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed May 2022.
68. Scherpereel A, Mazieres J, Greillier L, et al; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. *Lancet Oncol.* 2019 Feb;20(2):239-253. doi: 10.1016/S1473-2045(18)30765-4. Epub 2019 Jan 16. Erratum in: *Lancet Oncol.* 2019 Mar;20(3):e132.
69. Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med.* 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.
70. National Government Services, Inc. Local Coverage Article: Billing and Coding: Nivolumab (A54862). Centers for Medicare & Medicaid Services, Inc. Updated on 03/25/2022 with effective date 04/01/2022. Accessed May 2022.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C00.0	Malignant neoplasm of external upper lip
C00.1	Malignant neoplasm of external lower lip
C00.2	Malignant neoplasm of external lip, unspecified
C00.3	Malignant neoplasm of upper lip, inner aspect
C00.4	Malignant neoplasm of lower lip, inner aspect
C00.5	Malignant neoplasm of lip, unspecified, inner aspect
C00.6	Malignant neoplasm of commissure of lip, unspecified
C00.8	Malignant neoplasm of overlapping sites of lip
C00.9	Malignant neoplasm of lip, unspecified
C01	Malignant neoplasm of base of tongue
C02.0	Malignant neoplasm of dorsal surface of tongue
C02.1	Malignant neoplasm of border of tongue
C02.2	Malignant neoplasm of ventral surface of tongue
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified
C02.4	Malignant neoplasm of lingual tonsil
C02.8	Malignant neoplasm of overlapping sites of tongue
C02.9	Malignant neoplasm of tongue, unspecified



C03.0	Malignant neoplasm of upper gum
C03.1	Malignant neoplasm of lower gum
C03.9	Malignant neoplasm of gum, unspecified
C04.0	Malignant neoplasm of anterior floor of mouth
C04.1	Malignant neoplasm of lateral floor of mouth
C04.8	Malignant neoplasm of overlapping sites of floor of mouth
C04.9	Malignant neoplasm of floor of mouth, unspecified
C05.0	Malignant neoplasm of hard palate
C05.1	Malignant neoplasm of soft palate
C05.8	Malignant neoplasm of overlapping sites of palate
C05.9	Malignant neoplasm of palate, unspecified
C06.0	Malignant neoplasm of cheek mucosa
C06.2	Malignant neoplasm of retromolar area
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth
C06.9	Malignant neoplasm of mouth, unspecified
C09.0	Malignant neoplasm of tonsillar fossa
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)
C09.8	Malignant neoplasm of overlapping sites of tonsil
C09.9	Malignant neoplasm of tonsil, unspecified
C10.0	Malignant neoplasm of vallecula
C10.1	Malignant neoplasm of anterior surface of epiglottis
C10.2	Malignant neoplasm of lateral wall of oropharynx
C10.3	Malignant neoplasm of posterior wall of oropharynx
C10.4	Malignant neoplasm of branchial cleft
C10.8	Malignant neoplasm of overlapping sites of oropharynx
C10.9	Malignant neoplasm of oropharynx, unspecified
C11.0	Malignant neoplasm of superior wall of nasopharynx
C11.1	Malignant neoplasm of posterior wall of nasopharynx
C11.2	Malignant neoplasm of lateral wall of nasopharynx
C11.3	Malignant neoplasm of anterior wall of nasopharynx
C11.8	Malignant neoplasm of overlapping sites of nasopharynx
C11.9	Malignant neoplasm of nasopharynx, unspecified
C12	Malignant neoplasm of pyriform sinus
C13.0	Malignant neoplasm of postcricoid region
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect

C13.2	Malignant neoplasm of posterior wall of hypopharynx
C13.8	Malignant neoplasm of overlapping sites of hypopharynx
C13.9	Malignant neoplasm of hypopharynx, unspecified
C14.0	Malignant neoplasm of pharynx, unspecified
C14.2	Malignant neoplasm of Waldeyer's ring
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx
C15.3	Malignant neoplasm of upper third of esophagus
C15.4	Malignant neoplasm of middle third of esophagus
C15.5	Malignant neoplasm of lower third of esophagus
C15.8	Malignant neoplasm of overlapping sites of esophagus
C15.9	Malignant neoplasm of esophagus, unspecified
C16.0	Malignant neoplasm of cardia
C16.1	Malignant neoplasm of fundus of stomach
C16.2	Malignant neoplasm of body of stomach
C16.3	Malignant neoplasm of pyloric antrum
C16.4	Malignant neoplasm of pylorus
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified
C16.8	Malignant neoplasm of overlapping sites of stomach
C16.9	Malignant neoplasm of stomach, unspecified
C17.0	Malignant neoplasm of duodenum
C17.1	Malignant neoplasm of jejunum
C17.2	Malignant neoplasm of ileum
C17.3	Meckel's diverticulum, malignant
C17.8	Malignant neoplasm of overlapping sites of small intestine
C17.9	Malignant neoplasm of small intestine, unspecified
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified

**OPDIVO® (nivolumab) Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2022, Magellan Rx Management

C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.0	Malignant neoplasm of anus, unspecified
C21.1	Malignant neoplasm of anal canal
C21.2	Malignant neoplasm of cloacogenic zone
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal
C22.0	Liver cell carcinoma
C22.8	Malignant neoplasm of liver, primary, unspecified as to type
C22.9	Malignant neoplasm of liver, not specified as primary or secondary
C24.1	Malignant neoplasm of ampulla of Vater
C30.0	Malignant neoplasm of nasal cavity
C31.0	Malignant neoplasm of maxillary sinus
C31.1	Malignant neoplasm of ethmoidal sinus
C32.0	Malignant neoplasm of glottis
C32.1	Malignant neoplasm of supraglottis
C32.2	Malignant neoplasm of subglottis
C32.3	Malignant neoplasm of laryngeal cartilage
C32.8	Malignant neoplasm of overlapping sites of larynx
C32.9	Malignant neoplasm of larynx, unspecified
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung

**OPDIVO® (nivolumab) Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2022, Magellan Rx Management

C43.0	Malignant melanoma of lip
C43.10	Malignant melanoma of unspecified eyelid, including canthus
C43.11	Malignant melanoma of right eyelid, including canthus
C43.12	Malignant melanoma of left eyelid, including canthus
C43.111	Malignant melanoma of right upper eyelid, including canthus
C43.112	Malignant melanoma of right lower eyelid, including canthus
C43.121	Malignant melanoma of left upper eyelid, including canthus
C43.122	Malignant melanoma of left lower eyelid, including canthus
C43.20	Malignant melanoma of unspecified ear and external auricular canal
C43.21	Malignant melanoma of right ear and external auricular canal
C43.22	Malignant melanoma of left ear and external auricular canal
C43.30	Malignant melanoma of unspecified part of face
C43.31	Malignant melanoma of nose
C43.39	Malignant melanoma of other parts of face
C43.4	Malignant melanoma of scalp and neck
C43.51	Malignant melanoma of anal skin
C43.52	Malignant melanoma of skin of breast
C43.59	Malignant melanoma of other part of trunk
C43.60	Malignant melanoma of unspecified upper limb, including shoulder
C43.61	Malignant melanoma of right upper limb, including shoulder
C43.62	Malignant melanoma of left upper limb, including shoulder
C43.70	Malignant melanoma of unspecified lower limb, including hip
C43.71	Malignant melanoma of right lower limb, including hip
C43.72	Malignant melanoma of left lower limb, including hip
C43.8	Malignant melanoma of overlapping sites of skin
C43.9	Malignant melanoma of skin, unspecified
C44.00	Unspecified malignant neoplasm of skin of lip
C44.02	Squamous cell carcinoma of skin of lip
C44.09	Other specified malignant neoplasm of skin of lip
C45.0	Mesothelioma of pleura
C45.1	Mesothelioma of peritoneum
C45.2	Mesothelioma of pericardium
C45.7	Mesothelioma of other sites
C45.9	Mesothelioma, unspecified
C4A.0	Merkel cell carcinoma of lip
C4A.10	Merkel cell carcinoma of eyelid, including canthus

C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal
C4A.21	Merkel cell carcinoma of right ear and external auricular canal
C4A.22	Merkel cell carcinoma of left ear and external auricular canal
C4A.30	Merkel cell carcinoma of unspecified part of face
C4A.31	Merkel cell carcinoma of nose
C4A.39	Merkel cell carcinoma of other parts of face
C4A.4	Merkel cell carcinoma of scalp and neck
C4A.51	Merkel cell carcinoma of anal skin
C4A.52	Merkel cell carcinoma of skin of breast
C4A.59	Merkel cell carcinoma of other part of trunk
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip
C4A.71	Merkel cell carcinoma of right lower limb, including hip
C4A.72	Merkel cell carcinoma of left lower limb, including hip
C4A.8	Merkel cell carcinoma of overlapping sites
C4A.9	Merkel cell carcinoma, unspecified
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus
C51.2	Malignant neoplasm of clitoris
C51.8	Malignant neoplasm of overlapping sites of vulva
C51.9	Malignant neoplasm of vulva, unspecified
C53.0	Malignant neoplasm of endocervix
C53.1	Malignant neoplasm of exocervix
C53.8	Malignant neoplasm of overlapping sites of cervix uteri
C53.9	Malignant neoplasm of cervix uteri, unspecified
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C58	Malignant neoplasm of placenta

C61	Malignant neoplasm of prostate
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
C66.1	Malignant neoplasm of right ureter
C66.2	Malignant neoplasm of left ureter
C66.9	Malignant neoplasm of unspecified ureter
C67.0	Malignant neoplasm of trigone of bladder
C67.1	Malignant neoplasm of dome of bladder
C67.2	Malignant neoplasm of lateral wall of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.7	Malignant neoplasm of urachus
C67.8	Malignant neoplasm of overlapping sites of bladder
C67.9	Malignant neoplasm of bladder, unspecified
C68.0	Malignant neoplasm of urethra
C69.30	Malignant neoplasm of unspecified choroid
C69.31	Malignant neoplasm of right choroid
C69.32	Malignant neoplasm of left choroid
C69.40	Malignant neoplasm of unspecified ciliary body
C69.41	Malignant neoplasm of right ciliary body
C69.42	Malignant neoplasm of left ciliary body
C69.60	Malignant neoplasm of unspecified orbit
C69.61	Malignant neoplasm of right orbit
C69.62	Malignant neoplasm of left orbit
C76.0	Malignant neoplasm of head, face and neck
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum

C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct
C79.31	Secondary malignant neoplasm of brain
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C7A.1	Malignant poorly differentiated neuroendocrine tumors
C7B.1	Secondary Merkel cell carcinoma
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes
C81.27	Mixed cellularity Hodgkin lymphoma, spleen
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites

**OPDIVO® (nivolumab) Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2022, Magellan Rx Management

C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites
C81.70	Other Hodgkin lymphoma unspecified site
C81.71	Other Hodgkin lymphoma lymph nodes of head, face, and neck
C81.72	Other Hodgkin lymphoma intrathoracic lymph nodes
C81.73	Other Hodgkin lymphoma intra-abdominal lymph nodes
C81.74	Other Hodgkin lymphoma lymph nodes of axilla and upper limb
C81.75	Other Hodgkin lymphoma lymph nodes of inguinal region and lower limb
C81.76	Other Hodgkin lymphoma intrapelvic lymph nodes
C81.77	Other Hodgkin lymphoma spleen
C81.78	Other Hodgkin lymphoma lymph nodes of multiple sites
C81.79	Other Hodgkin lymphoma extranodal and solid organ sites
C81.90	Hodgkin lymphoma, unspecified site
C81.91	Hodgkin lymphoma, unspecified lymph nodes of head, face, and neck
C81.92	Hodgkin lymphoma, unspecified intrathoracic lymph nodes
C81.93	Hodgkin lymphoma, unspecified intra-abdominal lymph nodes
C81.94	Hodgkin lymphoma, unspecified lymph nodes of axilla and upper limb
C81.95	Hodgkin lymphoma, unspecified lymph nodes of inguinal region and lower limb
C81.96	Hodgkin lymphoma, unspecified intrapelvic lymph nodes
C81.97	Hodgkin lymphoma, unspecified spleen
C81.98	Hodgkin lymphoma, unspecified lymph nodes of multiple sites
C81.99	Hodgkin lymphoma, unspecified extranodal and solid organ sites
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb

**OPDIVO® (nivolumab) Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2022, Magellan Rx Management



C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes
C84.Z7	Other mature T/NK-cell lymphomas, spleen
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C86.0	Extranodal NK/T-cell lymphoma, nasal type
D09.0	Carcinoma in situ of bladder
D37.01	Neoplasm of uncertain behavior of lip
D37.02	Neoplasm of uncertain behavior of tongue
D37.05	Neoplasm of uncertain behavior of pharynx
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity
D37.1	Neoplasm of uncertain behavior of stomach
D37.8	Neoplasm of uncertain behavior of other specified digestive organs
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified
D38.0	Neoplasm of uncertain behavior of larynx
D38.5	Neoplasm of uncertain behavior of other respiratory organs
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified
D39.2	Neoplasm of uncertain behavior of placenta
O01.9	Hydatidiform mole, unspecified
Z85.00	Personal history of malignant neoplasm of unspecified digestive organ
Z85.01	Personal history of malignant neoplasm of esophagus
Z85.028	Personal history of other malignant neoplasm of stomach
Z85.038	Personal history of other malignant neoplasm of large intestine
Z85.068	Personal history of other malignant neoplasm of small intestine
Z85.118	Personal history of other malignant neoplasm of bronchus and lung
Z85.51	Personal history of malignant neoplasm of bladder
Z85.59	Personal history of malignant neoplasm of other urinary tract organ

**OPDIVO® (nivolumab) Prior Auth Criteria**

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2022, Magellan Rx Management

Z85.71	Personal history of Hodgkin lymphoma
Z85.820	Personal history of malignant melanoma of skin
Z85.821	Personal history of Merkel cell carcinoma

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA):

<b>Jurisdiction(s):</b> 6, K	<b>NCD/LCD/LCA Document (s):</b> A54862
<a href="https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=a54862&amp;areaId=all&amp;docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP">https://www.cms.gov/medicare-coverage-database/new-search/search-results.aspx?keyword=a54862&amp;areaId=all&amp;docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP</a>	

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC